Reuter Chemische Apparatebau Kg

Mitsubishi Gas Chemical Company, Inc.

Bridge Pharma Inc.

Biolotus Biotechnology Ag

Reuter Chemischer Apparatebau Kg

Janssen Pharmaceutica Nv

Syngenta Crop Protection, Inc.

Intervet International B.v.

Reuter Chemische Apparatebau E.k.

Reuter Chemische Apparatebau Kg [de/de]

Reuter Chemische Apparatebau Kg &lsqb;de/de&rsqb;

Reuter Chemicscher Apparatebau Kg

Lumavita Ag

Karl Reuter

Florian Stolz

Viktor Meier

Mark Kantor

Vasyl Andrushko

Tobias Wedel

Noriyuki Kato

Shinya Ikeda

Koji Hirose

Kentaro Ishihara

A K Gunnar Aberg

Mitsuteru Kondo

Munenori Shiratake

Kensuke Oshima

Milan Soukup

Eliso Gogritchiani

Dieter Krimmer

Cees Winninps

Jofzsef Balint

Shoko Suzuki

Manabu Hirakawa

Shuya Nagayama

Adrian Maurer

Michael Justus

Oliver Krebs

Tobias Strittmatter

Christian Krueger

Shoko Murata

Christoph Michlig

Philipp Kuenti

Victor Meier

Oliver Floegel

Cheng Yi Chen

Provided is a thermoplastic resin including constituent units represented by general formula (1). (In formula (1), R1 and R2 each independently represent: a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; an iodine atom; a C1-6 alkyl group; a monocyclic or polycyclic C6-36 aryl group; a monocyclic or polycyclic heteroaryl group having 5-36 ring atoms, 1, 2, 3, or 4 of the ring atoms being selected from nitrogen, sulfur, and oxygen, and the other ring atoms being carbon in the heteroaryl group; a C2-6 alkenyl group; a C1-6 alkoxy group; or a C7-17 aralkyl group. In formula (1), X, a, and bare each as described in the present specification.)

Thermoplastic resin, method for manufacturing same, and optical lens

The present invention relates to a process for the preparation of enantiomerically enriched 3-aminopiperidine, as in particular of its R-enantiomer (R)-3-aminopiperidine. The invention also relates to an enantiomerically enriched intermediate of said process and to specific acid-addition salts of 3-aminopiperidine (hereinafter also APIP) that are useful for obtaining a single enantiomer of APIP, and to crystalline (R)-3-aminopiperidine-dihydrochloride-monohydrate and crystalline (S)-3-aminopiperidine-dihydrochloride-monohydrate.

Process for the preparation of enantiomerically enriched 3-aminopiperidine

The present invention relates to triarylmethane compounds of the formula (I), which suitable as monomers for preparing thermoplastic resins having beneficial optical properties and which can be used for producing optical devices. R, Rare e.g. hydrogen; Y is an alkylene group having 2, 3 or 4 carbon atoms, Ar is selected from mono- or polycyclic aryl and mono- or polycyclic hetaryl; X, X, X, Xare CH, C&#x2014;Ror N, provided that in each ring at most two of X, X, X, Xare N; Ris e.g. halogen, CN or CH&#x2550;CH. The invention also relates to thermoplastic resins comprising a polymerized unit of the compound of formula (I).

Triarylmethane compounds

The present invention relates to a process for the preparation of enantiomerically enriched 3-aminopiperidine, as in particular of its R-enantiomer (R)-3-aminopiperidine. The invention also relates to an enantiomerically enriched intermediate of said process and to specific acid-addition salts of 3-aminopiperidine (hereinafter also APIP) that are useful for obtaining a single enantiomer of APIP, and to crystalline (R)-3-aminopiperidine-dihydrochloride-monohydrateand crystalline (S)-3-aminopiperidine-dihydrochloride-monohydrate.

The present invention relates to binaphthyl compounds of the formula (I), which are suitable as monomers for preparing polycarbonate resins having beneficial optical properties and which can be used for producing optical lenses: Formula (I) where X is C-C-alkandiyl or C-C-alkandiyl-C(O)&#x2014;, where C(O) is bound to the oxygen atom of the hydroxyl group and where C-C-alkandiyl or C-C-alkandiyl, respectively, are unsubstituted or carry a phenyl ring; R and R' are identical or different and selected from mono or polycyclic aryl having from 6 to 36 carbon atoms and mono- or polycyclic hetaryl having a total of 5 to 36 atoms, which are ring members, where 1, 2, 3 or 4 of these atoms are selected from nitrogen, sulfur and oxygen, while the remainder of these atoms are carbon atoms, where mono- or polycyclic aryl and mono- or polycyclic hetaryl are unsubstituted or carry 1 or 2 radicals R, which are selected from the group consisting of CN, CH, OCH, O-phenyl, O-naphthyl, S-phenyl, S-naphthyl, CI or F; and, if X is C-C-alkandiyl-C(O)&#x2014;, the esters thereof, in particular the C-C-alkylesters thereof. 

Binaphthyl compounds

The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. The present invention is further directed to an (S)-CSA salt of S-ketamine, more particularly a monohydrate form of the (S)-CSA salt of S-ketamine; and to an (R)-CSA salt of R-ketamine.

(S)-CSA salt of S-ketamine, (R)-CSA salt of S-ketamine and processes for the preparation of S-ketamine

The present invention relates to a process for the preparation of enantiomerically enriched 3-aminopiperidine, and in particular of its R-enantiomer (R)-3-aminopiperidine. The invention also relates to an enantiomerically enriched intermediate of said process and to specific acid-addition salts of 3-aminopiperidine (hereinafter also APIP) that are useful for obtaining a single enantiomer of APIP, and to crystalline (R)-3-aminopiperidine-dihydrochloride-monohydrate and crystalline (S)-3-aminopiperidine-di-hydrochloride-monohydrate.

Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin.

Highly pure pentamycin

Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin. 

The invention relates to a process for preparing chiral octenoic acid derivatives, which constitute important intermediates in the preparation of medicament active ingredients, and also to novel intermediates which are used in the process for preparing the octenoic acid derivatives mentioned.

Process for preparing octenoic acid derivatives

Process for preparing chiral octenoic acid derivatives

This invention generally relates to processes for making a crystalline zilpaterol salt, particularly zilpaterol hydrochloride. This invention also relates to methods of treatment using a crystalline zilpaterol salt prepared in accordance with this invention to increase the rate of weight gain, improve feed efficiency, and/or increase carcass leanness in livestock, poultry, and fish.

Process for making a crystalline zilpaterol salt

A method of promoting weight loss in animals or humans by administering thereto a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed.

Use of RR/SR-ractopamine

A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.

A method for purifying substances through emulsion crystallisation is described, whereby (a) an emulsion of organic liquid droplets in a continuous water phase containing the impure substance is formed; (b) the emulsion is super-saturated in the substance; (c) crystallisation of the substance in the water phase is induced; (d) the crystals of the substance are isolated from the from emulsion, yielding an emulsion-filtrate; (e) additional impure substance is dissolved in the emulsion-filtrate; and (f) steps (b)-(d) are repeated with the emulsion obtained from step (e).

Emulsion crystallisation with recycle

Growing community of inventors

Gundelfingen, Germany

Karl Reuter